摘要
目的探讨人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)与细胞增殖抗原Ki67在乳腺癌组织中的表达及其临床意义。方法 188例乳腺癌患者,采用免疫组织化学法检测乳腺癌组织HER-2与Ki67表达情况,分析其与临床病理特征的关系。结果 HER-2与Ki67在乳腺癌组织中的阳性率分别为63.83%、76.60%;HER-2表达在患者年龄、淋巴结转移、临床分期及雌激素受体表达上差异有统计学意义(P<0.05),在肿瘤大小和孕激素受体表达上差异无统计学意义(P>0.05);Ki67表达在淋巴结转移状况和临床分期上差异有统计学意义(P<0.05),在患者年龄、肿瘤大小、雌激素受体及孕激素受体表达上差异无统计学意义(P>0.05);HER-2阴性表达者Ki67阳性率(76.47%)与HER-2阳性表达者(73.33%)比较差异无统计学意义(P>0.05)。结论 HER-2与Ki67阳性表达可作为评估乳腺癌发生、发展的重要生物学指标;结合患者年龄、肿瘤大小、淋巴结转移状况、临床分期及雌激素受体、孕激素受体的表达等临床病理学因素,有助于患者临床分期的判断。
Objective To explore the expressions of human epidermal growth factor receptor-2（HER-2）and proliferating antigen Ki67 in breast cancer and the clinical significances.Methods The clinical data of 188 patients with breast cancer were collected.The expressions of HER-2and Ki67 were assessed by immunohistochemistry,and their correlations with clinicopathological factors were statistically analyzed.Results The positive rates of HER-2and Ki67 were 63.83% and 76.60%.The expression of HER-2 was correlated with the patient＇s age,lymph node metastasis,clinical stages and expression of estrogen receptor（ER）（P〈0.05）,but not correlated with tumor size or expression of progesterone receptor（PR）（P〉0.05）.The expression of Ki67 was correlated with lymph node metastasis and clinical stages,and not correlated with the patient＇s age,tumor size,ER or PR（P〉0.05）.The positive rate of Ki67 showed no significant difference between patients with negative and positive HER-2expression（76.47% vs 73.33%）（P〉0.05）.Conclusion The expressions of HER-2and Ki67 can be used as the important biological markers for estimating the development and progression of breast cancer.Combination of HER-2and Ki67 with the patient＇s age,tumor size,lymph node metastasis,clinical stages,ER and PR contributes to the judgement of the clinical stage of breast cancer.
出处
《中华实用诊断与治疗杂志》
2015年第2期166-168,共3页
Journal of Chinese Practical Diagnosis and Therapy
